Research in Social and Administrative Pharmacy
Volume 5, Issue 3 , Pages 274-285 , September 2009

Policies and institutional arrangements for rationalizing drug selection and consumption patterns in African healthcare systems

  • Ebenezer Kwabena Tetteh, B.Pharm., MSc

      Affiliations

    • The author is a pharmacist with an MSc in Health Policy, Planning and Financing from the London School of Economics and London School of Hygiene and Tropical Medicine. At the time of writing this article, the author worked at the Centre for Health Technology Evaluation of the National Institute for Health and Clinical Excellence, UK. The opinions expressed are entirely those of the author. No external funding was used in support of the article.

References 

  1. WHO. Promoting Rational Use of Medicines: Core Components. WHO/EDM/2002.3. 2002a.
  2. WHO. The World Medicines Situation. WHO/EDM/PAR/2004.5. 2004a.
  3. Elbasha EH. Deadweight loss of bacterial resistance due to over-treatment. Health Econ. 2003;12:125–138
  4. WHO. 2006. Progress in the rational use of medicines, including better medicines for children. Report by the Secretariat: 120th Session of the Executive Board. Available at: ftp.who.int/gb/ebwha/pdf_files/EB120/b120_7-en.pdf Accessed September 29, 2007.
  5. Laing RO, Hogerzeil HV, Ross-Degnan D. Ten recommendations to improve drug use in developing countries. Health Policy Plan. 2001;16(1):13–20
  6. WHO. The Selection of Essential Medicines. WHO/EDM/2002.2. 2002b.
  7. US FDA . Approved drug products with therapeutic equivalence evaluations. Available at: http://www.fda.gov/cder/ob/docs/preface/eclink.htm2007;Accessed April 27, 2007
  8. Schweitzer SO. Pharmaceutical Economics and Policy. New York: Oxford University Press; 1997;
  9. WHO . How to develop a national formulary based on the WHO model formulary: a practical guide. WHO/EDM/PAR/2004.8. 2004;
  10. Tetteh EK. Providing affordable essential medicines to African households: the missing policies and institutions for price containment. Soc Sci Med. 2008;66(3):569–581
  11. World Bank . Importance of pharmaceuticals and essential drug programs in Better Health for Africa: experience and lessons learned. Available at www.worldbank.org1994;AccessedJune 5, 2006
  12. Mossialos E. Regulating expenditures on medicines in European health care systems. In:  Saltman RB,  Figueras J,  Sakellarides C editor. Critical challenges for health sector reform in Europe. Maidenhead: Open University Press; 1999;p. 261–283
  13. WHO . A short manual on Tanzania National Drug policy: the masterplan for the pharmaceutical sector 1992-2000. Available at http://82.77.46.162:8080/gsd/cgi-bin/whocountry/library.fcgi1993;Accessed October 5, 2007
  14. Yudkin JS. The economics of pharmaceutical supply in Tanzania. Int J Health Serv. 1980;10(3):455–477
  15. Kuhn M. Quality in Primary Care: Economic Approaches to Analyzing Quality-Related Physician Behaviour. London: Office of Health Economics; 2003;
  16. Chaix-Couturier C, Durand-Zaleski I, Jolly D, Durieux P. Effects of financial incentives on medical practice: results from a systematic review of literature and methodological issues. Int J Qual Health care. 2000;12(2):133–142
  17. Robinson JC. Theory and practice in the design of physician payment incentives. Milbank Q. 2001;79(2):149–177
  18. Propper C, Wilson D. The use of performance measures in healthcare systems. In:  Jones A editors. The Elgar companion to health economics. Cheltenham: Edward Elgar; 2006;p. 326–334
  19. Soeters R, Musango L, Meessen B. Comparisons of two output-based schemes in Butare and Cyangugu provinces with two control provinces in Rwanda. Global Partnership on Output-Based Aid (GPOBA). Rwanda: World Bank, Ministry of Health; 2005;
  20. Meessen B, Kashala J-P, Musango L. Output-based payment to boost staff productivity in public health centers: Contracting in Kabutare district, Rwanda. Bulletin of the World Health Organisation. 2007;85:108–115
  21. Partridge MR. Translating research into practice: how are guidelines implemented?. Eur Respir J. 2003;21(Suppl. 39):23–29
  22. Levine S, Campen D, Millares M, Barrueta A. Kaiser Permanente's prescription drug benefit. Health Affairs. 2000;19(2):185–190
  23. Pagnoni F, Convelbo N, Tiendrebeogo J, Cousens S, Esposito F. A community-based programme to provide prompt and adequate treatment of presumptive malaria in children. Trans Royal Soc Trop Med Hyg. 1997;91(5):512–517
  24. Gafni A, Charles C, Whelan T. The physician-patient encounter: the physician as a perfect agent for the patient versus the informed treatment decision-making model. Soc Sci Med. 1998;47(3):347–354
  25. Horne R. Patients' beliefs about treatment: The hidden determinant of treatment outcome?. J Psychosom Res. 1999;47(6):491–495
  26. Lamiraud K, Geoffard P-V. Therapeutic non-adherence: A rational behaviour revealing patient preferences?. Health Econ. 2007;16:1185–1204
  27. Etkin N, Ross J, Muazzamu T. The indigenization of pharmaceuticals: therapeutic transitions in rural Hausaland. Soc Sci Med. 1990;30(8):919–928
  28. Bradley C, Hansen EH, Kooiker S. Patients and Their Medicines. In:  Mossialos E,  Mrazek M,  Walley T editor. Regulation of pharmaceuticals in Europe: striving for efficiency, equity and quality. Maidenhead: Open University Press; 2004;p. 158–176
  29. Loevinsohn BP. Health education interventions in developing countries: a methodological review of published articles. Int J Epidemiol. 1990;19(4):788–794
  30. Wright JM, Htun Y, Leong MG, Forman P, Ballard RC. Evaluation of the use of calendar blister packaging on patient compliance with STD syndromic treatment regimens. Sex Transm Dis. 1999;26(10):556–563
  31. Kidane G, Morrow RH. Teaching mothers to provide home treatment of malaria in Tigray, Ethiopia: a randomized trial. Lancet. 2000;356(9229):550–555
  32. Pauly MV. Nonprofit firms in medical markets. Am Econ Rev. 1987;77(2):257–262
  33. Le Grand J. Motivation, agency and public policy: of knights & knaves, pawns & queens. New York: Oxford University Press; 2003;
  34. Maiga FI, Haddad S, Fournier SP, Gauvin L. Public and private sector responses to essential drugs: a multilevel analysis of drug prescription and selling practices in Mali. Soc Sci Med. 2003;57(5):937–948
  35. Conway S, White S. Co-creating health systems. Presentation at Re-Action, 16 May 2006. Available at http://www.who.int/management/meetings/en/index6.html2006;Accessed August 1 2008

PII: S1551-7411(08)00093-4

doi: 10.1016/j.sapharm.2008.08.007

Research in Social and Administrative Pharmacy
Volume 5, Issue 3 , Pages 274-285 , September 2009

Article Tools

* Image Usage & Resolution